A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Condition:   Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions:   Drug: Atezolizumab;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Not yet recruiting

http://ift.tt/2F9bXAP